MEREO BIOPHARMA (MREO)
(Delayed Data from NSDQ)
$1.74 USD
-0.03 (-1.69%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.73 -0.01 (-0.57%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Mereo BioPharma Group plc - Sponsored ADR's return on equity, or ROE, is -80.00% compared to the ROE of the Medical - Biomedical and Genetics industry of -66.95%. While this shows that MREO has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
MREO 1.74 -0.03(-1.69%)
Will MREO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MREO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MREO
RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End
MEREO BIOPHARMA (MREO) Upgraded to Buy: What Does It Mean for the Stock?
MREO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for MREO
Fell Below 20 Day Moving Average appears for MREO after 1.69% move
Crossed Above 20 Day Moving Average appears for MREO after 2.31% move
Is MREO signaling selling opportunity? Fell Below 20 Day Moving Average shows up after dropping 1.7%
50 Day Moving Average Resistance appears for MREO after 0.0% move
Fell Below 50 Day Moving Average appears for MREO after 4.86% move